Rhenman & Partners Asset Management AB Decreases Stake in Encompass Health Corporation $EHC

Rhenman & Partners Asset Management AB trimmed its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 12.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 119,400 shares of the company’s stock after selling 17,000 shares during the quarter. Encompass Health accounts for about 1.7% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 22nd biggest position. Rhenman & Partners Asset Management AB owned approximately 0.12% of Encompass Health worth $15,166,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Citizens National Bank Trust Department purchased a new position in shares of Encompass Health during the 3rd quarter valued at approximately $26,000. First Horizon Corp bought a new position in Encompass Health during the 3rd quarter valued at $34,000. Westside Investment Management Inc. increased its position in shares of Encompass Health by 56.7% in the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock worth $35,000 after purchasing an additional 101 shares during the last quarter. Assetmark Inc. increased its position in shares of Encompass Health by 88.1% in the 3rd quarter. Assetmark Inc. now owns 299 shares of the company’s stock worth $38,000 after purchasing an additional 140 shares during the last quarter. Finally, Root Financial Partners LLC acquired a new stake in shares of Encompass Health in the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on EHC shares. Barclays boosted their price objective on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Zacks Research downgraded Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Finally, Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, January 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $143.29.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 150,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total value of $16,746,000.00. Following the sale, the chief executive officer directly owned 377,070 shares of the company’s stock, valued at $42,096,094.80. This trade represents a 28.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.00% of the stock is currently owned by insiders.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $106.89 on Friday. The company has a market cap of $10.63 billion, a PE ratio of 19.29, a P/E/G ratio of 2.05 and a beta of 0.71. Encompass Health Corporation has a fifty-two week low of $92.53 and a fifty-two week high of $127.99. The firm has a 50-day simple moving average of $103.93 and a 200 day simple moving average of $113.65. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 5th. The company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.17. The company had revenue of $3.09 billion during the quarter, compared to the consensus estimate of $1.54 billion. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.Encompass Health’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.17 earnings per share. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. On average, sell-side analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, April 1st. Encompass Health’s dividend payout ratio is presently 13.72%.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.